Only in Titles

           Search results for: Mycoplasma pneumoniae IgM ELISA kit   

paperclip

#24147043   2013/10/22 Save this To Up

High seroprevalence of Mycoplasma pneumoniae IgM in acute Q fever by enzyme-linked immunosorbent assay (ELISA).

Q fever is serologically cross-reactive with other intracellular microorganisms. However, studies of the serological status of Mycoplasma pneumoniae and Chlamydophila pneumoniae during Q fever are rare. We conducted a retrospective serological study of M. pneumoniae and C. pneumoniae by enzyme-linked immunosorbent assay (ELISA), a method widely used in clinical practice, in 102 cases of acute Q fever, 39 cases of scrub typhus, and 14 cases of murine typhus. The seropositive (57.8%, 7.7%, and 0%, p<0.001) and seroconversion rates (50.6%, 8.8%, and 0%, p<0.001) of M. pneumoniae IgM, but not M. pneumoniae IgG and C. pneumoniae IgG/IgM, in acute Q fever were significantly higher than in scrub typhus and murine typhus. Another ELISA kit also revealed a high seropositivity (49.5%) and seroconversion rate (33.3%) of M. pneumoniae IgM in acute Q fever. The temporal and age distributions of patients with positive M. pneumoniae IgM were not typical of M. pneumoniae pneumonia. Comparing acute Q fever patients who were positive for M. pneumoniae IgM (59 cases) with those who were negative (43 cases), the demographic characteristics and underlying diseases were not different. In addition, the clinical manifestations associated with atypical pneumonia, including headache (71.2% vs. 81.4%, p=0.255), sore throat (8.5% vs. 16.3%, p=0.351), cough (35.6% vs. 23.3%, p=0.199), and chest x-ray suggesting pneumonia (19.3% vs. 9.5%, p=0.258), were unchanged between the two groups. Clinicians should be aware of the high seroprevalence of M. pneumoniae IgM in acute Q fever, particularly with ELISA kits, which can lead to misdiagnosis, overestimations of the prevalence of M. pneumoniae pneumonia, and underestimations of the true prevalence of Q fever pneumonia.

2166 related Products with: High seroprevalence of Mycoplasma pneumoniae IgM in acute Q fever by enzyme-linked immunosorbent assay (ELISA).

Mycoplasma pneumoniae IgM Alkaline Phospatase (ALP) GLP 1 ELISA Kit, Rat Gluc Screen Quest™ Colorimet Screen Quest™ Colorimet Screen Quest™ Fluorimet Screen Quest™ Fluorimet Infection diseases: Heli Human high sensitivity in EnzyChrom™ Kinase Assay Leptin ELISA Kit, Human A MarkerGene™ Cellular Se

Related Pathways

paperclip

#21144026   2011/01/17 Save this To Up

Identification of an N-terminal 27 kDa fragment of Mycoplasma pneumoniae P116 protein as specific immunogen in M. pneumoniae infections.

Mycoplasma pneumoniae is an important cause of respiratory tract infection and is increasingly being associated with other diseases such as asthma and extra-pulmonary complications. Considerable cross-reactivity is known to exist between the whole cell antigens used in the commercial serological testing assays. Identification of specific antigens is important to eliminate the risk of cross-reactions among different related organisms. Adherence of M. pneumoniae to human epithelial cells is mediated through a well defined apical organelle to which a number of proteins such as P1, P30, P116 and HMW1-3 have been localized, and are being investigated for adhesion, gliding and immunodiagnostic purposes.

1448 related Products with: Identification of an N-terminal 27 kDa fragment of Mycoplasma pneumoniae P116 protein as specific immunogen in M. pneumoniae infections.

Apoptosis Phospho-Specifi EGF Phospho-Specific Arra Rabbit Anti-APIP Apaf1 In Rabbit Anti-APIP Apaf1 In Polyclonal Antibody Inter Proteins and Antibodies H Native M. pneumoniae Anti Mouse Anti-S. pneumoniae Mycoplasma pneumoniae Ant Polyclonal Antibody Recep HIV 1 intergase antigen. BACTERIOLOGY MYCOPLASMA P

Related Pathways

paperclip

#20701743   2010/09/06 Save this To Up

Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae.

Mycoplasma pneumoniae is responsible for acute respiratory tract infections (RTIs) common in children and young adults. As M. pneumoniae is innately resistant to beta-lactams antibiotics usually given as the first-line treatment for RTIs, specific and early diagnosis is important in order to select the right treatment. Serology is the most used diagnostic method for M. pneumoniae infections.

2021 related Products with: Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae.

AtpB | beta subunit of AT AtpB | beta subunit of AT ATP synthase H+ transport pCMVLuxB Mammalian LuxB E Anti-ATPase, (Na(+) K(+)) Anti ATPase, (Na(+) K(+)) anti GSK3 Beta IgG2a (mon BACTERIOLOGY MYCOPLASMA P MYCOPLASMA PNEUMONIAE M12 succinate-CoA ligase, GDP ATPase beta3(Na+ K+) anti ATP synthase C mature ant

Related Pathways

paperclip

#15980029   2005/08/12 Save this To Up

Mycoplasma pneumoniae infection in children with acute respiratory infection.

A prospective study was performed on 93 children admitted to Kasturba Medical College Hospital, Manipal and TMA Pai Rotary Hospital of Udupi and Karkala. Blood samples from 93 children admitted to the ward with no respiratory illness were taken as age-matched controls for the inpatients, IgM antibody against Mycoplasma pneumoniae was detected using a commercial kit (Virion-Serion ELISA, Germany) following the manufacturer's instructions. 23.96% of the inpatients with respiratory tract symptoms had IgM antibodies against Mycoplasma pneumoniae. The highest infection rate was found to be in the 2-5 and 5-10 year age group. The most common mode of presentation was an upper respiratory focus of infection with cervical lymphadenopathy. Bronchial breathing signifying pneumonic consolidation was significantly less in the Mycoplasma positive group (p = 0.006). There was no statistically significant difference in the radiological findings in the Mycoplasma positive and Mycoplasma negative groups.

1792 related Products with: Mycoplasma pneumoniae infection in children with acute respiratory infection.

Infection diseases: Heli Infection diseases: Heli Liver cancer tissue array Liver tissue cancer tissu Hepatocellular carcinoma BACTERIOLOGY MYCOPLASMA P MYCOPLASMA PNEUMONIAE M12 Mycoplasma pneumoniae IgA Mycoplasma pneumoniae IgG Mycoplasma pneumoniae IgM Mycoplasma pneumoniae Ant Syringe pump can be contr

Related Pathways

  •  
  • No related Items
paperclip

#12806926   2003/06/16 Save this To Up

[Evaluation of a rapid IgM antibody detection kit for diagnosis of Mycoplasma pneumoniae infection during childhood].

We evaluated the utility of a rapid detection kit for Mycoplasma pneumoniae (Mp)-specific IgM antibody, ImmunoCard (IC) Mycoplasma Test (Meridian Bioscience, USA), with regard to mycoplasmal infection during childhood. For this purpose, 30 serum samples were obtained from 23 pediatric patients with serologically proved mycoplasmal pneumonia at and younger than 16 years of age. The diagnosis of mycoplasmal infection was made by means of a particle agglutination (PA) method, which was on the basis of 1) a four fold or greater rise with paired sera or 2) at and more than 1:640 with a single, acute phase serum. In addition to the IC test, Mp-specific IgM and IgG antibodies were measured by ELISA tests (Zeus, USA) for comparison. A final observation time for colorization in the IC test was prolonged to 10 min in this study. The reason for this was because only 8 samples which were obtained 5 days or more after the onset of fever (37.5 degrees C) were judged to be positive when the observation time was confined to 5 min as the manufacturer recommended. A judgment was always made by more than one persons. Since we intended to find out the diagnostic capability of the IC test using an acute phase single serum, we focused on 18 cases for which samples were obtained within 5 days of the onset of fever. As a result, 13 (72%) cases were judged to be positive for Mp by the IgM ELISA test, 6 (33%) cases, including 5 cases in which the result was interpreted to be positive by a 10-min observation, were judged to be positive by the IC test, and 4 (22%) cases were judged to be positive by the PA test when titers of at and more than 1:320 by an acute phase single serum were interpreted as significant. Through this study we felt that the sensitivity of the IC test was not so high as have been previously reported in the literatures (the IC test was occasionally positive even in the range of < 1:40 by a PA test). On the other hand, we believe that the 10-min observation for final colorization did not significantly affect the specificity of the IC test as long as it was compared with the results by the ELISA IgM test. So far, the rapidity in obtaining results, and the simplicity of handling by which the test can be performed in an outpatient clinic, are thought to be the major advantages of the IC test.

2452 related Products with: [Evaluation of a rapid IgM antibody detection kit for diagnosis of Mycoplasma pneumoniae infection during childhood].

Beta Amyloid (40) ELISA K Beta Amyloid (1 42) ELISA Antibody array detection Rapid Mouse Ig Isotyping Rapid Mouse Ig Isotyping Rapid Mouse Ig Isotyping Human anti-parainfluenza Human heparin (Hep) antib Human borrelia burgdorfer MarkerGeneTM Fluorescent MOUSE ANTI HUMAN CD15, Pr Mycoplasma pneumoniae IgM

Related Pathways

paperclip

#12376023   2002/10/11 Save this To Up

Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD.

A prospective study was conducted to identify and characterize hospitalizations for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with serologic evidence of infection with Mycoplasma pneumoniae (Mp). Two hundred forty hospitalizations for AECOPD were included in a 17-month prospective study. Paired sera were obtained for each of the hospitalizations and were tested serologically for Mp using a commercial enzyme immunoassay (EIA) kit. Only significant changes, according to the formula in the manufacturer's instructions, in antibody titers for IgM and/or IgG and/or IgA were considered diagnostic for Mp infection. In 34 hospitalizations (14.2%) the serologic tests for Mp were positive (MpH). In 29 of these hospitalizations (85%) a significant change in IgA was found. In 11 of these hospitalizations (32%) the only change identified was in IgA. In 24 MpH (71%) there was serologic evidence for infection with at least one other respiratory pathogen. In comparison to the 206 hospitalizations without serologic evidence of infection with Mp, MpH had higher rates of inhaled steroid therapy (41% vs. 24%, p = 0.033) and a longer time interval between the appearance of dyspnea and hospitalization (6.6 +/- 3.8 days vs. 5.0 +/- 3.5 days, p = 0.012). There were no significant differences between these two groups in a broad spectrum of patient- and exacerbation-related clinical variables. Specific antibiotic therapy for Mp in the MpH group did not shorten the hospital stay. Serologic evidence of Mp infection is common in patients hospitalized for AECOPD, and is usually based on changes in specific IgA antibody titers. In most MpH another respiratory pathogen can be identified. The vast majority of clinical characteristics are the same in patients with and without serologic evidence of infection with Mp. The practical implications of these findings should be clarified in further studies.

2720 related Products with: Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD.

BACTERIOLOGY MYCOPLASMA P MYCOPLASMA PNEUMONIAE M12 Infection diseases: Heli Infection diseases: Heli Liver cancer tissue array Liver tissue cancer tissu Hepatocellular carcinoma Ofloxacin CAS Number [824 Mycoplasma pneumoniae IgA Mycoplasma pneumoniae IgG Mycoplasma pneumoniae IgM Mycoplasma pneumoniae Ant

Related Pathways

  •  
  • No related Items
paperclip

#10681711   2000/06/20 Save this To Up

[Rapid detection of Mycoplasma pneumoniae-specific IgM].

The rapid diagnosis of Mycoplasma pneumoniae infection is important in carrying out chemotherapy in appropriate manner. It is also essential to detect the specific immunoglobulin M (IgM) in order to diagnose infectious diseases. The ImmunoCard Mycoplasma kit (TFB. Inc./Meridian Diagnostics, Inc.) is a 10-min-card-based enzyme-linked immunosorbent assay (ELISA) of IgM antibodies to M. pneumoniae. The ImmunoCard was compared with high density particle agglutination (HDPA) and cold hemagglutinin (CHA). The ImmunoCard test had 98.3% sensitivity, 51.4% specificity, and 72.5% agreement with HDPA (>or =320), but it had 94.3% sensitivity, 87.5% specificity, and 92.2% agreement with clinical diagnosis. Our results indicate that the ImmunoCard Mycoplasma IgM assay is a rapid, simple and valuable procedure which can be analyze small numbers of specimens using a less complicated technique and with no other equipment required. This means that the ImmunoCard is a cost-effective, energy saving and rapid procedure for the detection of M. pneumoniae-specific IgM.

1061 related Products with: [Rapid detection of Mycoplasma pneumoniae-specific IgM].

Mycoplasma pneumoniae IgM BACTERIOLOGY MYCOPLASMA P MYCOPLASMA PNEUMONIAE M12 Mycoplasma Pneumonia IgM C.pneumoniae IgM goat IgG against monkey I MOUSE ANTI HUMAN CD15, Pr Mycoplasma pneumoniae IgA Mycoplasma pneumoniae IgG Mycoplasma pneumoniae Ant MOUSE ANTI HUMAN CD15, Pr Rapid Microplate Assay K

Related Pathways

paperclip

#9790139   1998/12/08 Save this To Up

Evaluation of Meridian ImmunoCard Mycoplasma test for the detection of Mycoplasma pneumoniae-specific IgM in paediatric patients.

The Meridian ImmunoCard Mycoplasma kit, a 10-min card-based enzyme-linked immunosorbent assay (ELISA) designed to detect immunoglobulin M (IgM) antibodies to Mycoplasma pneumoniae was evaluated. We compared the ImmunoCard with the Fujirebio Serodia Myco II particle agglutination test, as well as with the complement fixation (CF) test to detect M. pneumoniae antibodies in paediatric patients. The ImmunoCard test and Serodia Myco II test agreed in 93.95%, and ImmunoCard test and CF test agreed in 83.51% of the 182 specimens tested. Nine specimens gave negative particle agglutination titres in the acute phase sample, and 28 specimens gave negative CF titres in the acute phase sample, although in the ImmunoCard test they were positive. These results may indicate that the ImmunoCard assay detects lower IgM levels of antibodies than the Serodia Myco II and CF test. The ImmunoCard appears to be a good screening assay test for M. pneumoniae IgM in children in whom M. pneumoniae IgM is found frequently.

1066 related Products with: Evaluation of Meridian ImmunoCard Mycoplasma test for the detection of Mycoplasma pneumoniae-specific IgM in paediatric patients.

Mycoplasma pneumoniae IgM Multiple organ tumor tiss Mycoplasma pneumoniae IgA Mycoplasma pneumoniae IgG BACTERIOLOGY MYCOPLASMA P MYCOPLASMA PNEUMONIAE M12 Infection diseases: Heli Mycoplasma Pneumonia IgM C.pneumoniae IgM Multiple organ cancer tis MOUSE ANTI HUMAN CD15, Pr Mycoplasma pneumoniae Ant

Related Pathways

paperclip

#8727899   1996/10/24 Save this To Up

Performance of Meridian ImmunoCard Mycoplasma test in a multicenter clinical trial.

Serology is the principal laboratory method used to diagnose Mycoplasma pneumoniae infection. Meridian Diagnostics has developed the ImmunoCard Mycoplasma kit, a 10-min card-based enzyme-linked immunosorbent assay (ELISA) designed to detect immunoglobulin M (IgM) antibodies to M. pneumoniae. We compared the ImmunoCard with two M. pneumoniae IgM-specific assays (immunofluorescence assay [IFA] and ELISA) and a standard complement fixation (CF) procedure using 896 specimens submitted to clinical laboratories for M. pneumoniae serology. Equivocal results obtained by CF, IFA, or ELISA were resolved by testing with an additional method or by reviewing patient chart information. The ImmunoCard had sensitivities ranging from 74% compared with the ELISA to 96% compared with CF results with IFA. ImmunoCard specificities ranged from 85% compared with the IgM-specific ELISA to 98% compared with IgM-specific IFA results resolved with clinical chart review. We also compared the ImmunoCard results with consensus results of 694 specimens tested on at least two non-ImmunoCard methods because of the lack of a "gold standard" for M. pneumoniae serology. Overall, the ImmunoCard Mycoplasma IgM assay had 90% sensitivity, 93% specificity, and 92% agreement with the consensus results. The ImmunoCard is technically less complex and requires less equipment that the three other assays. Our results indicate that the ImmunoCard Mycoplasma IgM assay is a valid and simple procedure which can reduce technologist time (and, thus, labor cost) and turnaround time for laboratories analyzing small numbers of specimens (< 10 per batch) submitted for IgM anti-M. pneumoniae testing.

2427 related Products with: Performance of Meridian ImmunoCard Mycoplasma test in a multicenter clinical trial.

Multiple organ tumor tiss Embryonal tumor test tiss Embryonal tumor test tiss Endocrine organ cancer te Stomach cancer test tissu Stomach cancer test tissu Stomach cancer test tissu Esophageal cancer test ti Esophagus carcer test tis Esophageal cancer test ti Liver cancer test tissue Liver cancer test tissue

Related Pathways